Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 9/20 | 0.49 |
| ▸ | BMPR1A | P36894 | 9/20 | 0.49 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 9/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.49 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510757 | 0.98 | BMPR1B (0.48) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL27361980 | 0.87 | BMPR1B (0.40) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL8126458 | 0.85 | ATAD2 (0.59) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL5107121 | 0.84 | ATAD2 (0.48) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL5116354 | 0.83 | ATAD2 (0.43) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL2061861 | 0.83 | ATAD2 (0.49) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL5501201 | 0.82 | ATAD2 (0.43) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL14528011 | 0.81 | BMPR1B (0.50) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL25315122 | 0.80 | BMPR1B (0.49) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL22667214 | 0.80 | BMPR1B (0.52) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119604493-A | Heterocyclic compounds as BCL6 modulators useful as ligand-directed degradants | 细胞基因公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4514473-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20090149520-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | PFIZER INC | 2009-06-11 | — | — | US | disclosed |
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | PFIZER INC | 2008-10-23 | — | — | US | disclosed |
| CN-101155806-A | Oxindole * oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN CO LTD (US) | 2008-04-02 | — | — | CN | disclosed |
| EP-1781643-A1 | OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | JOSYULA VARA PRASAD V N | 2006-10-12 | — | — | US | disclosed |
| WO-2006016220-A1 | OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | OXA1L, MRPL21, RPS27L | BMPR1B 3022/4885BMPR1A 2396/4885ACVRL1 2708/4885 |
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | OXA1L, OXSR1, OXER1 | BMPR1B 3345/4885BMPR1A 2725/4885ACVRL1 2482/4885 |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | BMPR1B 735/4885BMPR1A 832/4885ACVRL1 2010/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | BMPR1B 735/4885BMPR1A 832/4885ACVRL1 2010/4885 |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | BMPR1B 735/4885BMPR1A 832/4885ACVRL1 2010/4885 |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | BMPR1B 3285/4885BMPR1A 2586/4885ACVRL1 2910/4885 |
| US-20090149520-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | OXA1L, MT-ND4L, IL4I1 | BMPR1B 4515/4885BMPR1A 4303/4885ACVRL1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.